Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy
Genovese, M. C., Hsia, E., Belkowski, S. M., Chien, C., Masterson, T., Thurmond, R. L., Manthey, C. L., Yan, X., Ge, T., Franks, C., Greenspan, A.Language:
english
Journal:
The Journal of Rheumatology
DOI:
10.3899/jrheum.141580
Date:
August, 2015
File:
PDF, 1.18 MB
english, 2015